



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/819,094	03/27/2001	Richard I. Weiner	UCSF-018/02US	6968

7590 08/12/2002

Karl Bozicevic
Bozicevic, Field & Francis, LLP
200 Middlefield Road, Suite 200
Menlo Park, CA 94025

EXAMINER

BRANNOCK, MICHAEL T

ART UNIT PAPER NUMBER

1646

DATE MAILED: 08/12/2002 12

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No. 09/819,094	Applicant(s) Welner et al.
Examiner Michael Brannock, Ph.D	Art Unit 1646



— The MAILING DATE of this communication appears on the cover sheet with the correspondence address —

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on Mar 14, 2002

2a) This action is FINAL. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle* 1835 C.D. 11; 453 O.G. 213.

4) Claim(s) 1-26 is/are pending in the application.

4a) Of the above, claim(s) _____ is/are withdrawn from consideration.

5) Claim(s) _____ is/are allowed.

6) Claim(s) _____ is/are rejected.

7) Claim(s) _____ is/are objected to.

8) Claims 1-26 are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on _____ is/are a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

11) The proposed drawing correction filed on _____ is: a) approved b) disapproved by the Examiner.
If approved, corrected drawings are required in reply to this Office action.

12) The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All b) Some* c) None of:
1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. _____.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

*See the attached detailed Office action for a list of the certified copies not received.

14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).
a) The translation of the foreign language provisional application has been received.

15) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413) Paper No(s). _____

2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 5) Notice of Informal Patent Application (PTO-152)

3) Information Disclosure Statement(s) (PTO-1449) Paper No(s). _____ 6) Other: _____

DETAILED ACTION

Election/Restriction

1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 1-5, drawn to polypeptides, classified in class 530, subclass 350.
 - II. Claims 6-20, drawn to polynucleotides and methods of producing a polypeptide, classified in class 536, subclass 23.5.
 - III. Claims 21-24 and 26, drawn to methods of treating disorders, classified in class 514, subclass 2.
 - IV. Claim 25, drawn to methods of diagnosis, classified in class 436, subclass 501.
2. The inventions are distinct, each from the other because of the following reasons:

Although there are no provisions under the section for “Relationship of Inventions” in M.P.E.P. § 806.05 for inventive groups that are directed to different products, restriction is deemed to be proper because these products appear to constitute patentably distinct inventions for the following reasons: Groups I and II are directed to products that are distinct both physically and functionally, and are not required one for the other, and are therefore patentably distinct. Further, the protein of Group I can be prepared by processes which are materially different from recombinant DNA expression of Group II, such as by chemical synthesis, or by isolation and purification from natural sources. Additionally, the DNA of Group II can be used other than to make the protein of Group I, such in gene therapy or as a probe in nucleic acid hybridization assays.

Art Unit: 1646

Although there are no provisions under the section for “Relationship of Inventions” in M.P.E.P. § 806.05 for inventive groups that are directed to different methods, restriction is deemed to be proper because these methods appear to constitute patentably distinct inventions for the following reasons: Groups III and IV are directed to methods that are distinct both physically and functionally, and are not required one for the other. Group III requires administration of polypeptide, which is not required by group IV. Group IV requires an assay of endogenous protein expression, which is not required by III.

The polypeptides of Group I are related to the methods of Groups III and IV as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the polypeptides of Group I are patentably distinct from each of the methods of Groups III and IV because the polypeptides can be used in ways that are materially and functionally different than each of the methods because, as discussed above, each of the methods of Groups III and IV are materially and functionally distinct from each other.

The polynucleotides of Group II are related to the methods of Groups III and IV as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially

Art Unit: 1646

different process of using that product (MPEP § 806.05(h)). In the instant case the polynucleotides of Group II are patentably distinct from each of the methods of Groups III and IV because the polynucleotides can be used in ways that are materially and functionally different than each of the methods because, as discussed above, each of the methods of Groups III and IV are materially and functionally distinct from each other.

Therefore, because these inventions are distinct for the reasons given above and because a search and examination of all the groups in one patent application would result in an undue burden, since the searches for the groups are not co-extensive, the classification is different, and the subject matter is divergent, restriction for examination purposes as indicated is proper.

3. This application contains claims directed to the following patentably distinct species of the claimed invention: polypeptides of SEQ ID NO: 18, 24, 30, polynucleotides of SEQ ID NO: 14, 20, 26, 19, 13, and 25. Each polypeptide and polynucleotide is a chemically distinct molecule, the use of one not being required for the use of any other. Although a search of any one of the species may overlap that of another, the search of one species could not be relied upon, solely, to provide art that is anticipatory or would render obvious the invention of any other species, and to search all species would be burdensome.

Regardless of the Group elected, Applicant is required under 35 U.S.C. 121 to further elect a single disclosed species for prosecution on the merits to which the claims shall be

Art Unit: 1646

restricted if no generic claim is finally held to be allowable. Currently, claims 1, 2, 6-9, 16-21, 25 and 26 are generic.

4. Further, if Applicant elects for prosecution Group III, applicant is required to additionally elect a species of disorder, such species being defined as that involving a single identifiable patient population, e.g. a placental vascularization disorder or tumor formation, each disorder having distinct etiologies and requiring divergent treatment steps and goals. A search of one disorder could not be relied upon to, solely, to provide art that is anticipatory or would render obvious the treatment of any other disorder, and to search all species of disorders would be burdensome.

If Applicant elects Group III, Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 21 and 22 are generic to the treatment of disorders.

5. Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Art Unit: 1646

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

6. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

7. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Art Unit: 1646

8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael Brannock, Ph.D., whose telephone number is (703) 306-5876. The examiner can normally be reached on Mondays through Thursdays from 8:00 a.m. to 5:30 p.m. The examiner can also normally be reached on alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne Eyler, Ph.D., can be reached at (703) 308-6564.

Official papers filed by fax should be directed to (703) 308-4242. Faxed draft or informal communications with the examiner should be directed to (703) 308-0294.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

MB *WY*
August 9, 2002

Yvonne Eyler
YVONNE EYLER, PH.D
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600